Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain

Journal of Pain Research

Volumn 3, Issue , 2010, Pages 161-168

  Anderson, Stephanie ^a,b   Krug, Hollis ^a,b   Dorman, Christopher ^a   McGarraugh, Pari ^a   Frizelle, Sandra ^a   Mahowald, Maren ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Intra articular BoNT B; Osteoarthritis

Indexed keywords

BOTULINUM TOXIN B; MYOBLOC;

ADULT; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EVOKED PAIN RESPONSE SCORE; GAIT; KNEE ARTHRITIS; KNEE PAIN; LIMB WEAKNESS; MOUSE; NONHUMAN; SCORING SYSTEM; STRENGTH;

EID: 84856901484     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S12520     Document Type: Article

References (28)

1. Hochberg MC. Multidisciplinary integrative approach to treating knee pain in patients with osteoarthritis. Ann Intern Med. 2003; 139: 724-730.
2. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58: 26-35.
3. CDC.gov. Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Osteoarthritis. 2009 Aug 1 [updated 2010 Feb 4]. Available at: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm. Accessed May 23, 2010.
4. McAlindon T, Cooper C, Kirwan J, Dieppe P. Knee pain and disability in the community. Br J Rheumatol. 1992; 23: 189-192.
5. Ettinger W, Davis M, Neurhaus J, Mallon K. Long-term physical functioning in persons with knee osteoarthritis from NHANES I: Effects of comorbid medical conditions. J Clin Epidemiol. 1994; 47: 809-815.
6. Mahowald M. The role of nonprescription analgesics in treating mild to moderate pain. Clinical and economic considerations. Minneapolis Health Learning Systems. 2000.
7. Mahowald M. Chronic pain management. In: Ruddy S, Harris E, Sledge C, Budd R, Sergent J, editors. Kelley’s Textbook of Rheumatology. Philadelphia, PA: WB Saunders; 2004.
8. Moseley JB, O’Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002; 347: 81-88.
9. Kirkley A, Birmingham TB, Litchfield RB, et al. A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2008; 359: 1097-1107.
10. Curatolo M, Bogduk N. Pharmacologic pain treatment of musculoskeletal disorders: Current perspectives and future prospects. Clin J Pain. 2001; 17: 25-32.
11. Kidd BL. Osteoarthritis and joint pain. Pain. 2006; 123: 6-9.
12. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: New insight. Part 1: The disease and its risk factors. Ann Intern Med. 2000; 133: 635-646.
13. Schaible HG, Schmelz M, Tegeder I. Pathophysiology and treatment of pain in joint disease. Adv Drug Deliv Rev. 2006; 58: 323-342.
14. Mahowald ML, Singh JA, Dykstra D. Long term effects of intraarticular botulinum Type A for refractory joint pain. Neurotox Res. 2006; 9: 179-188.
15. Mahowald ML, Krug HE, Singh JA, et al. Intra-articular botulinum toxin type A: A new approach to treat arthritis joint pain. Toxicon. 2009; 54: 658-667.
16. Krug HE, Frizelle S, McGarraugh P, et al. Pain behavior measures to quantitate joint pain and response to neurotoxin treatment in murine models of arthritis. Pain Med. 2009; 10: 1218-1228.
17. Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: A randomized, double-blinded, placebo-controlled trial. Transl Res. 2009; 153: 205-216.
18. Lam FF, Wong HH, Ng ES. Time course and substance P effects on the vascular and morphological changes in adjuvant-induced monoarthritic rats. Int Immunopharmacol. 2004; 4: 299-310.
19. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006; 13 Suppl 4: 1-9.
20. Flynn TC. Myobloc. Dermatol Clin. 2004; 22: 207-211.
21. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum serotypes. Eur J Neurol. 2001: 8 Suppl 5: 21-29.
22. Aoki KR. Botulinum toxin: A successful therapeutic protein. Curr Med Chem. 2004; 11: 3085-3092.
23. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain. 2002; 6 Suppl: S147-S154.
24. Aoki KR. Evidence for antinociceptive activity of botulinum toxin Type A in pain management. Headache. 2003; 43 Suppl 1: S9-S15.
25. Purkiss J, Welch M, Doward S, et al. Capsaicin stimulated release of substance P from cultured dorsal root ganglion neurons involvement of two distinct mechanisms. Biochem Pharmacol. 2000; 59: 1403-1406.
26. Cui M, Li Z, You S, et al. Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing. Arch Pharmacol. 2002; 365: R17.
27. Dykstra D. The effects of intra-articular botulinum toxin on sacroiliac, cervical/lumbar facet and sternoclavicular joint pain and C-2 root and lumbar disc pain: A case series of 11 patients. The Pain Clinic. 2007; 19: 27-32.
28. Boon AJ, Smith J, Dahm DL, et al. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: A pilot study. PM R. 2010; 2: 268-276.